BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope

Decade after first approval, bispecifics on the precipice of going mainstream

If fulfilled, CVR tied to pipeline programs would drive deal’s value even further

CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch

Part 2 of an interview with AstraZeneca’s head of oncology

Global biotech sees Brukinsa and pipeline as growth engines as it relies on ‘CRO-free’ R&D model, protects supply chain

Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem

Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM

‘No change’ to strategy of seeking bolt-ons worth $5B or less, suggesting Cytokinetics takeout is unlikely